Migraine Clinical Trial
Official title:
Impact of Integrating a Disease-Specific Migraine App Into the Management of Patients in the Primary Care Setting
Verified date | July 2020 |
Source | Eli Lilly and Company |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine whether using a smart phone application to foster communication between study participants and their doctor will impact care. Participants must have a history of migraine or have recently been prescribed a common medicine to treat migraine. The study will last about one year for each participant.
Status | Completed |
Enrollment | 120 |
Est. completion date | April 26, 2019 |
Est. primary completion date | April 26, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Have a diagnosis of migraine (ICD10: G43.*) since October 2015 OR a record of being prescribed a triptan prior to study - Have not been prescribed a preventive migraine medication within the past twelve months - Have not visited a neurologist in the past year - Have an upcoming visit with their Atrium Health primary care provider Exclusion Criteria: - Do not own an iOS or Android smart phone with a data plan or are unwilling to install the app on their phone - Are currently participating in a clinical trial involving an investigational drug - Have previously used the app used in this study - Are pregnant at the time of study entry - Are not able to provide informed consent - Cannot speak and read English fluently |
Country | Name | City | State |
---|---|---|---|
United States | Carmel Family Physicians | Charlotte | North Carolina |
United States | Charlotte Internal Medicine | Charlotte | North Carolina |
United States | Charlotte Medical Clinic | Charlotte | North Carolina |
United States | Charlotte Medical Clinic-South Park | Charlotte | North Carolina |
United States | Mecklenburg Medical Group - Ballantyne | Charlotte | North Carolina |
United States | Randolph Internal Medicine | Charlotte | North Carolina |
United States | South Charlotte Primary Care | Charlotte | North Carolina |
United States | Shiland Family Fort Mill | Fort Mill | South Carolina |
United States | Shiland Family Practice | Fort Mill | South Carolina |
United States | Table Rock Family Medicine | Glen Alpine | North Carolina |
United States | Mecklenburg Medical Group - Northcross | Huntersville | North Carolina |
United States | North Charlotte Medical Specialists - Huntersville | Huntersville | North Carolina |
United States | Lincoln Family Practice | Lincolnton | North Carolina |
United States | Mecklenburg Medical Group - Matthews | Matthews | North Carolina |
United States | Union Family Practice | Monroe | North Carolina |
United States | Troy Medical Services | Troy | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Eli Lilly and Company | Atrium Health |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants Receiving a Preventive Migraine Prescription | Number of Participants Receiving a Preventive Migraine Prescription | Next primary care appointment following use of app (estimated as 5 weeks) | |
Secondary | Number of Months of App Use | Number of Months of App Use | Baseline through one year | |
Secondary | Number of Participants Receiving Acute and Preventive Migraine Treatments, Opioids, Barbiturates | Number of Participants Receiving Acute and Preventive Migraine Treatments, Opioids, Barbiturates | Baseline through one year | |
Secondary | Number of Acute Care Visits | Number of Acute Care Visits | Baseline through one year | |
Secondary | Number of Primary Care Visits | Number of Primary Care Visits | Baseline through one year | |
Secondary | Number of Emergency Room Visits | Number of Emergency Room Visits | Baseline through one year | |
Secondary | Number of Urgent Care Visits | Number of Urgent Care Visits | Baseline through one year | |
Secondary | Number of Referrals to a Neurologist | Number of Referrals to a Neurologist | Baseline through one year | |
Secondary | Number of New Diagnoses of Migraine or Chronic Migraine | Diagnoses made by International Classification of Diseases 10th revision (ICD10) coding system | Baseline through one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05525611 -
Cabergoline as a Preventive Treatment for Chronic Migraine
|
N/A | |
Completed |
NCT06192173 -
Patent Foramen Ovale Closure in Migraine
|
||
Recruiting |
NCT03832998 -
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
|
Phase 3 | |
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
Completed |
NCT06304675 -
Manageable Environmental Factors in Migraine
|
||
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
Completed |
NCT04179474 -
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
|
Phase 1 | |
Recruiting |
NCT04603976 -
Registry for Migraine - Clinical Core
|
Phase 4 | |
Completed |
NCT03597529 -
CHOCOlate MeLatonin for AdolescenT MigrainE
|
Phase 2 | |
Completed |
NCT04197349 -
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
|
Phase 1 | |
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Active, not recruiting |
NCT05064371 -
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
|
Phase 3 | |
Suspended |
NCT04069572 -
Vibratory Stimulation for the Treatment of Chronic Pain
|
N/A | |
Not yet recruiting |
NCT04859374 -
Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach
|
N/A | |
Not yet recruiting |
NCT03083860 -
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.
|
N/A | |
Completed |
NCT02905227 -
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
|
Phase 1 | |
Enrolling by invitation |
NCT02532023 -
The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients
|
Phase 4 | |
Completed |
NCT02108678 -
One-Day Intervention for Depression and Impairment in Migraine Patients
|
N/A |